Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells

Chinese Journal of Oncology

Volumn 36, Issue 9, 2014, Pages 645-650

  Yang, Zhenli ^a   Li, Zhanwen ^a   Feng, Hailiang ^a   Bian, Xiaocui ^a   Liu, Yanyan ^a   Liu, Yuqin ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Carcinoma; Inhibitor; K ras gene; MEK; Non small cell lung; PI3K

Indexed keywords

CYCLIN B1; CYCLIN D1; K RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PICTILISIB; PROTEIN BAX; PROTEIN BCL 2; SELUMETINIB; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; KRAS PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; TARGET OF RAPAMYCIN KINASE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH INHIBITION; LUNG CANCER CELL LINE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NON SMALL CELL LUNG CANCER CELL; PROTEIN EXPRESSION; WESTERN BLOTTING; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BENZIMIDAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84929938917     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2014.09.002     Document Type: Article

References (10)

1. Forde PM, Etlinger DS. Targeted therapy for non-small-cell lung cancer; past, present and future [J]. Expert Rev Anticancer Ther, 2013, 13(6):745-758.
2. Raparia K, Villa C, DeCamp MM, et al. Molecular profiling in non-small cell lung cancer; a step toward personalized medicine [J]. Arch Pathol Lab Med, 2013, 137(4):481-491.
3. Cancer Genome Atlas Research Network, Kandolh C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma [J]. Nature, 2013, 497(7447);67-73.
4. Roberts PJ, Usary JE, Darr DB, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models [J]. Clin Cancer Res, 2012, 18(19): 5290-5303.
5. Haagensen EJ, Kyle S, Beale GS, et al. The synergistic interaction of MEK and P13K inhibitors is modulated by mTOR inhibition[J]. Br J Cancer, 2012, 106(8):1386-1394.
6. Brose MS In search of a real "targeted" therapy for thyroid cancer [J]. Clin Cancer Res, 2012, 18(7):1827-1829.
7. Roberts PJ, Stinchcombe TE. K-ras mutation: should we test for it, and does it matter? [J]. J Clin Oncol, 2013, 31 (8): 1112-1121.
8. Salphati L, Pang J, Plise EG, et al. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human[J]. Xenobiotica, 2011, 41 (12): 1088-1099.
9. Hoeflich KP, Merchant M, Orr C, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition [J]. Cancer Res, 2012, 72(1):210-219.
10. Saxena R, Chandra V, Manohar M, et al. Chemotherapeutic potential of 2-[piperidinoethoxyphenyl]-3-phenyl-2H-benzo (b) pyran in estrogen receptor-negative breast cancer cells; action via prevention of EGFR activation and combined inhibition of PI-3-K/ Akl/FOXO and MEK/Erk/AP-1 pathways[J]. PLoS One, 2013, 8(6):e66246.